Novavax Secures $2B in Funding to Support COVID-19 Vaccine Development

8/10/20

By Douglas W. House, SA

Novavax (NASDAQ:NVAX) Q2 results:

Revenue: $35.5M (+999%) from CEPI agreement.

Net loss: ($17.5M); loss/share: ($0.30).

Cash and equivalents at quarter-end: $424.4M (+438.6%).

Secured $2B in funding to support development and commercialization of COVID-19 vaccine candidate NVX-CoV2373.

READ FULL ARTICLE HERE

Recent Deals

Interested in advertising your deals? Contact Edwin Warfield.